Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis. We conducted a three-part, phase 3 trial in which ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Dupilumab is a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by type 2 inflammation, including eosi ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Getting a cold once or twice a few months is normal, but what about a persistently blocked nose that lingers for weeks and ...

There were significant differences in percentages of children with eosinophilic esophagitis who experienced histologic remission with dupilumab compared with placebo, according to a study ...

Dupilumab (Dupixent) is the first new treatment for chronic spontaneous urticaria in over a decade. Here’s the journey it took to FDA approval.

Dupilumab, a fully human monoclonal antibody, works by inhibiting the signaling of the interleukin 4 (IL-4) and IL-13 pathways and is approved for many conditions characterized by type 2 ...

A randomized placebo-controlled study found the monoclonal antibody dupilumab (Dupixent) led to histologic remission in significantly more affected children than placebo.

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

The FDA has approved these four biologics to treat atopic dermatitis: dupilumab, lebrikizumab, nemolizumab, and tralokinumab. They are all types of biologics called monoclonal antibodies.

Summary Scientists believe that monoclonal antibody drugs, including benralizumab and dupilumab, may be breakthrough emphysema treatments.